ConductScience.org, home

Paper39338387

Structural Basis for Monoclonal Antibody Therapy for Transthyretin Amyloidosis.

Chakrabartty A. Pharmaceuticals (Basel), 2024. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. Structural Basis for Monoclonal Antibody Therapy for Transthyretin Amyloidosis. Papers, record 39338387. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39338387

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Structural Basis for Monoclonal Antibody Therapy for Transthyretin Amyloidosis.
PubMed
Journal
Pharmaceuticals (Basel)
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
1.27, provisional
iCite
Revised in PubMed
2025-10-30
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chakrabartty AAvi

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P41 GM103311NIGMS NIH HHSUnited StatesP41GM103311PubMedNIH RePORTER
Sponsored Research AgreementProthena BiosciencesPubMedPubMed

Download CSV of grants

References53

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128218749Mechanistic basis for the recognition of a misfolded protein by the molecular chaperone Hsp90.Nat Struct Mol Biol2017https://conductscience.org/library/papers/28218749PubMed
222244854The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug.J Mol Biol2012https://conductscience.org/library/papers/22244854PubMed
327122057Substoichiometric inhibition of transthyretin misfolding by immune-targeting sparsely populated misfolding intermediates: a potential diagnostic and therapeutic for TTR amyloidoses.Sci Rep2016https://conductscience.org/library/papers/27122057PubMed
437285532Antibody-Associated Reversal of ATTR Amyloidosis-Related Cardiomyopathy.N Engl J Med2023https://conductscience.org/library/papers/37285532PubMed
51390650Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro.Biochemistry1992https://conductscience.org/library/papers/1390650PubMed
616185074Cys114-linked dimers of transthyretin are compatible with amyloid formation.Biochemistry2005https://conductscience.org/library/papers/16185074PubMed
734035264A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells.Nat Commun2021https://conductscience.org/library/papers/34035264PubMed
836795354RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis.BioDrugs2023https://conductscience.org/library/papers/36795354PubMed
910077645Exposure of cryptic epitopes on transthyretin only in amyloid and in amyloidogenic mutants.Proc Natl Acad Sci U S A1999https://conductscience.org/library/papers/10077645PubMed
1030145929Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.N Engl J Med2018https://conductscience.org/library/papers/30145929PubMed
1124648510Physiological IgM class catalytic antibodies selective for transthyretin amyloid.J Biol Chem2014https://conductscience.org/library/papers/24648510PubMed
1232929754Systemic amyloidosis from A (AA) to T (ATTR): a review.J Intern Med2021https://conductscience.org/library/papers/32929754PubMed
134968450Influence of age and sex on prealbumin levels.Clin Chim Acta1968https://conductscience.org/library/papers/4968450PubMed
1436399070Relationship of binding-site occupancy, transthyretin stabilisation and disease modification in patients with tafamidis-treated transthyretin amyloid cardiomyopathy.Amyloid2023https://conductscience.org/library/papers/36399070PubMed
1522378262Tafamidis.Nat Rev Drug Discov2012https://conductscience.org/library/papers/22378262PubMed
1624164623Transthyretin aggregate-specific antibodies recognize cryptic epitopes on patient-derived amyloid fibrils.Rejuvenation Res2014https://conductscience.org/library/papers/24164623PubMed
1737111614Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy.Pharmaceutics2023https://conductscience.org/library/papers/37111614PubMed
188639594The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid.Biochemistry1996https://conductscience.org/library/papers/8639594PubMed
199789022Inhibiting transthyretin conformational changes that lead to amyloid fibril formation.Proc Natl Acad Sci U S A1998https://conductscience.org/library/papers/9789022PubMed
20279930Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy.Proc Natl Acad Sci U S A1978https://conductscience.org/library/papers/279930PubMed

See all 53 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
42939656Transthyretin Amyloidosis: From Mechanisms to Treatment.Biomolecules2026https://conductscience.org/library/papers/42939656PubMed
42380466The antibody-peptide fusion protein, AT-02, is an effective opsonin with pan-amyloid reactivity.NPJ Drug Discov2025https://conductscience.org/library/papers/42380466PubMed
42228252Context-of-use-Guided Development and Validation of a Transthyretin Immunoassay: A Framework for Biomarker Assay Design.AAPS J2026https://conductscience.org/library/papers/42228252PubMed
41801500Transthyretin amyloid depletion therapy: lessons from the phase 2 trial of coramitug.Heart Fail Rev2026https://conductscience.org/library/papers/41801500PubMed
41309103[Diagnosis of Amyloidosis in Hand and Plastic Surgery Patients: Optimal Tissue Selection and Examination Methods for Early Detection].Handchir Mikrochir Plast Chir2026https://conductscience.org/library/papers/41309103PubMed
40649158Transthyretin Amyloid Cardiomyopathy-2025 Update: Current Diagnostic Approaches and Emerging Therapeutic Options.J Clin Med2025https://conductscience.org/library/papers/40649158PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
TTR7276PubTator's text mininghttps://conductscience.org/library/genes/7276

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39338387

GET https://conductscience.org/api/papers/v1/39338387/references?page=2